| 1.05 -0.023 (-2.16%) | 10-15 12:10 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.36 | 1-year : | 1.49 |
| Resists | First : | 1.17 | Second : | 1.27 |
| Pivot price | 1.07  |
|||
| Supports | First : | 0.99 | Second : | 0.82 |
| MAs | MA(5) : | 1.07 |
MA(20) : | 1.1 |
| MA(100) : | 0.95 |
MA(250) : | 0.94 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 36.4 |
D(3) : | 36.7 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 3.44 | Low : | 0.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TRIB ] has closed above bottom band by 33.9%. Bollinger Bands are 65.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.08 - 1.09 | 1.09 - 1.09 |
| Low: | 1.02 - 1.03 | 1.03 - 1.04 |
| Close: | 1.06 - 1.07 | 1.07 - 1.08 |
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Tue, 02 Sep 2025
After 6-Month Challenge: Biotech Diagnostic Maker Trinity Biotech Secures Crucial Nasdaq Listing Status - Stock Titan
Tue, 02 Sep 2025
Trinity Biotech plc Regains Compliance with Nasdaq Minimum Bid Price and Market Value Requirements - Quiver Quantitative
Wed, 27 Aug 2025
Trinity Biotech (NASDAQ:TRIB) investor five-year losses grow to 85% - Yahoo Finance
Thu, 21 Aug 2025
Trinity Biotech Appoints Paul Tivnan as Non-Executive Director - Yahoo Finance
Wed, 20 Aug 2025
TRIB’s Skyrocketing Shares: What’s Behind the Surge? - StocksToTrade
Wed, 20 Aug 2025
Major Manufacturing Shift: Trinity Biotech Transforms HIV Test Production with Dual Regulatory Approvals - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 4 (M) |
| Shares Float | 134 (M) |
| Held by Insiders | 12 (%) |
| Held by Institutions | 14.1 (%) |
| Shares Short | 96 (K) |
| Shares Short P.Month | 265 (K) |
| EPS | -1.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -1.97 |
| Profit Margin | -51.7 % |
| Operating Margin | -42.8 % |
| Return on Assets (ttm) | -10.6 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 18.1 % |
| Gross Profit (p.s.) | 5.74 |
| Sales Per Share | 16.5 |
| EBITDA (p.s.) | -3.5 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -0.59 |
| PEG Ratio | 0 |
| Price to Book value | -0.54 |
| Price to Sales | 0.06 |
| Price to Cash Flow | -0.94 |
| Dividend | 1.1 |
| Forward Dividend | 0 |
| Dividend Yield | 104.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|